Drug · CHEMBL514
LOMUSTINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LOMUSTINE. Drugs and targets, record CHEMBL514. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL514
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 4 of its 45 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases45
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 45Source Open Targets
See all 45 diseasesTrials95
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00085735 | Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma | Phase 3 | 549 | 2017-06-14 | lomustine | Its name | ClinicalTrials.gov |
| NCT00777153 | Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma | Phase 3 | 423 | 2012-12-21 | lomustine | Its name | ClinicalTrials.gov |
| NCT00004259 | Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas | Phase 3 | 230 | 2017-11-13 | lomustine | Its name | ClinicalTrials.gov |
| NCT01582269 | A Study in Recurrent Glioblastoma (GB) | Phase 2 | 158 | 2025-11-24 | lomustine | Its name | ClinicalTrials.gov |
| NCT02986178 | Lerapolturev in Recurrent Malignant Glioma | Phase 2 | 121 | 2025-07-11 | lomustine | Its name | ClinicalTrials.gov |
| NCT00100802 | Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas | Phase 2 | 118 | 2017-01-13 | lomustine | Its name | ClinicalTrials.gov |
| NCT01067469 | Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) | Phase 2 | 83 | 2020-03-17 | lomustine | Its name | ClinicalTrials.gov |
| NCT00504660 | 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients | Phase 2 | 75 | 2012-01-11 | lomustine | Its name | ClinicalTrials.gov |
| NCT04421378 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | Phase 1/2 | 74 | 2024-12-16 | lomustine | Its name | ClinicalTrials.gov |
| NCT03463265 | Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma | Phase 2 | 62 | 2023-11-07 | lomustine | Its name | ClinicalTrials.gov |
1 to 10 of 95
See all 95 trialsComparisons in its trials14
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Lerapolturev vs Lerapolturev + Lomustine: Number of Participants With Objective Radiographic Response | 5 of 93 | 2 of 27 | 120 | NCT02986178 | Trial comparisons |
| Lerapolturev vs Lerapolturev + Lomustine: Safety of Lerapolturev | 17 of 94 | 8 of 26 | 120 | NCT02986178 | Trial comparisons |
| Anaplastic Tumors vs Glioblastoma Multiforme: serious adverse events | 8 of 31 | 16 of 43 | 74 | NCT00504660 | Trial comparisons |
| Standard Dose Bevacizumab vs Low Dose Bevacizumab + Lomustine: serious adverse events | 9 of 36 | 9 of 35 | 71 | NCT01067469 | Trial comparisons |
| Standard Dose Bevacizumab vs Low Dose Bevacizumab + Lomustine: Summary of Treatment Related Toxicities | 0 of 36 | 24 of 33 | 69 | NCT01067469 | Trial comparisons |
| Standard Dose Bevacizumab vs Low Dose Bevacizumab + Lomustine: deaths from any cause | 6 of 36 | 1 of 33 | 69 | NCT01067469 | Trial comparisons |
| Trabedersen 10 µM vs Chemotherapy: serious adverse events | 6 of 13 | 0 of 11 | 24 | NCT00761280 | Trial comparisons |
| Arm I (CHOP) vs Arm II (Oral Chemotherapy): Number of Patients Who Complete Treatment | 3 of 4 | 1 of 3 | 7 | NCT01775475 | Trial comparisons |
| Arm I (CHOP) vs Arm II (Oral Chemotherapy): Proportion of Patients Who Are Adherent to Chemotherapy | 4 of 4 | 3 of 3 | 7 | NCT01775475 | Trial comparisons |
| Arm I (CHOP) vs Arm II (Oral Chemotherapy): Overall Response Rate | 3 of 4 | 1 of 3 | 7 | NCT01775475 | Trial comparisons |
1 to 10 of 14
See all 14 comparisons in its trialsPapers from its trials87
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials7
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Verbal Learning | 3 | 0 | ConductCognition |
| Trail Making Test A | 2 | 0 | ConductCognition |
| Verbal Fluency | 2 | 0 | ConductCognition |
| Block Copy Test | 1 | 0 | ConductCognition |
| Continuous Performance Test | 1 | 0 | ConductCognition |
| Finger Tapping Task | 1 | 0 | ConductCognition |
| Stroop Color-Word Test | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL514
GET https://conductscience.org/api/drugs/v1/CHEMBL514/diseases?page=2